MARKET WIRESeekingAlpha • 21h ago
OmniAb: A Self-Funding Option Book On 433 Partner ProgramsOmniAb reaches self-sustaining cash flow as its royalty platform gains traction.
Why OABI Stock slipped -0.95% Today — RQD Quant Desk Flash
$5.23 -0.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
OmniAb Inc. (OABI) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $760.4M
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OABI)Realized 20D OHLCV Swing Band: ±12.5%
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why OABI Stock slipped -0.95% Today — RQD Quant Desk Flash
OmniAb Inc. (OABI) slipped -0.95% to $5.23, trading at 95% of its 52-week range ($1.3 – $5.43). Stretched risk/reward at current multiples (-23% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 95% of its 52-week range ($1.3 – $5.43) with RSI-14 at 58.7 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $5.23 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live OABI Headlines & Catalysts
MARKET WIREYahoo • 1d ago
OmniAb, Inc. Q3 2026 Earnings Call SummaryMoby summary of OmniAb, Inc.'s Q3 2026 earnings call
CATALYSTYahoo • 2d ago
OmniAb (OABI) Q3 2026 Earnings Call TranscriptRevenue jumped to $4M as xPloration expands and Lilly partnership unlocks $3B in milestones.
MARKET WIREBenzinga • 2d ago
OmniAb Q3 2026 Earnings Call TranscriptOmniAb (NASDAQ:OABI) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For
CATALYSTYahoo • 2d ago
OmniAb Q3 Earnings Call HighlightsOmniAb (NASDAQ:OABI) reported higher third-quarter revenue and raised its full-year 2026 revenue and year-end cash outlook, citing partner-program milestones, expanding service revenue and early commercial progress for i
RISK WATCHSeekingAlpha • 2d ago
OmniAb, Inc. (OABI) Q3 2026 Earnings Call TranscriptOmniAb, Inc. (OABI) Q3 2026 Earnings Call October 30, 2026 8:00 AM EDTCompany ParticipantsKurt Gustafson - Executive VP of Finance & CFOMatthew Foehr -...
CATALYSTChartMill • 2d ago
OmniAb Inc. (NASDAQ:OABI) Q3 2026 Revenue Beat and Raised Guidance Offset by Sell-the-News PressureOmniAb Q3 2026 revenue beat and narrower loss, raised guidance, but OABI shares fell premarket on revenue quality and wide Q4 outlook.
RISK WATCHYahoo • 2d ago
OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue EstimatesOmniAb, Inc. (OABI) delivered earnings and revenue surprises of 0.00% and +10.12%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
RISK WATCHYahoo • 2d ago
OmniAb Reports Third Quarter 2026 Financial Results and Business HighlightsEMERYVILLE, Calif., October 30, 2026--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reported financial results for th
MARKET WIREBenzinga • 2d ago
12 Health Care Stocks Moving In Friday's Pre-Market SessionGainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity Therapeutics
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OABI)
- ✓Walkthrough of OABI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
OABI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +276.26%▲ ASCENDING CHANNEL
2026-10-30O $4.40H $5.23L $4.35C $5.23VOL 2.11M
RES: $7.10SUP: $2.50SMA50: $4.65SMA200: $2.70
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
OABI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -29.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on OABI today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for OABI. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OABI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OABI)
Health Care Rank #703 of 1016
⚔️ NRC vs OABI Full Matrix →
1. Head-to-Head Health Care Peer Comparison (OABI vs. NRC, ABSI, MXCT, ICLR)
Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, OmniAb Inc. (OABI) ranks #703 by composite RQD confidence (38/100, grade D-) and #392 by equity capitalization ($760.4M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. ICLR currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with OABI at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OABI
ACTIVE
OmniAb Inc. | D- | 38/100 | — | — | -22.6% | -0.95% | $760.4M | Benchmark Subject |
| NRC NRC Health | C | 65/100 | 44.8x | — | 21.0% | +0.09% | $519.6M | /nrc-vs-oabi → |
| ABSI Absci Corporation | D | 45/100 | — | — | -35.0% | +1.85% | $2.08B | /absi-vs-oabi → |
| MXCT MaxCyte Inc. | E | 30/100 | — | 96.0% | -27.1% | +1.17% | $178.5M | /mxct-vs-oabi → |
| ICLR ICON plc | B- | 71/100 | 71.9x | — | 3.1% | +0.62% | $16.50B | /iclr-vs-oabi → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001846253In its most recent audited fiscal period (FY2025, filed 2025-12-31), OmniAb Inc. (OABI) reported GAAP revenue of $18.7M (-29.3% vs. FY2024 revenue of $26.4M , and -45.4% cumulative change since FY2023) , GAAP net income of -$64.8M, operating cash flow of -$36.5M, and free cash flow of -$37.0M (+10.9% YoY). On the balance sheet, OABI closed FY2025 with $300.9M in total assets against $0 in total debt (Altman Z-Score: 12.19, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $18.7M | -$64.8M | -$36.5M | -$37.0M | $300.9M | — |
| FY2024 (FY) | 2024-12-31 | $26.4M | -$62.0M | -$39.7M | -$41.5M | $325.6M | — |
| FY2023 (FY) | 2023-12-31 | $34.2M | -$50.6M | $2.3M | $2.3M | — | — |
3. OABI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs OABI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, OmniAb Inc. (NASDAQ: OABI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $5.23 (-0.95% 1D, market cap $760.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OABI ranks #703 in composite RQD confidence.
How does OABI compare to NRC and ABSI in the Health Care sector?
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), OABI carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -22.6%. By comparison, NRC (NRC Health) holds a C grade (65/100 RQD, P/E 44.8x, ROIC 21.0%, cap $519.6M) and ABSI (Absci Corporation) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.08B). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for OABI?
Per OABI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001846253), OmniAb Inc. generated $18.7M in revenue (-29.3% YoY), -$64.8M in net income, and -$37.0M in free cash flow against $300.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is OABI trading relative to its 50-day, 200-day, and 52-week technical levels?
OABI last traded at $5.23 (-0.95% on volume of 1,683,619 shares), positioning the stock +12.47% above its 50-day simple moving average ($4.65) and +93.70% above its 200-day simple moving average ($2.70). Across its 52-week range of $1.30 to $5.43, OABI sits at the 95.2% percentile with a 14-day RSI of 58.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($4.58 to $5.88).
OABI Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is OABI stock moving today?
Why OABI Stock slipped -0.95% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-23% return on capital) under elevated 10-year interest-rate pressure.